Statistiques de base
| CIK | 1142790 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tauriga Sciences, Inc.
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| August 16, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-53723 ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report |
|
| July 14, 2022 |
NT 10-K/A 1 formnt10-ka.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25/A Amendment No. 1 NOTIFICATION OF LATE FILING SEC File Number: 000-53723 ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran |
|
| June 30, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-53723 ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Tran |
|
| November 23, 2021 |
Tauriga Sciences Announces Results of Special Meeting of Shareholders Held on November 22, 2021 Exhibit 99.1 Tauriga Sciences Announces Results of Special Meeting of Shareholders Held on November 22, 2021 New York, New York 11/23/2021. ?Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or the ?Company?), a New York based diversified Life Sciences Company, today announced the results of its Special Meeting of stockholders held on November 22, 2021. At the Special Meeting, Tauriga?s stockholders |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30- |
|
| November 15, 2021 |
Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| November 15, 2021 |
Convertible Redeemable Note with GS Capital Partners, LLC dated August 25, 2021 Exhibit 10.3 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $105,0 |
|
| November 15, 2021 |
Securities Purchase Agreement with MBS GLOEQ Corp dated October 11, 2021 Exhibit 4.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of October 11, 2021, by and between TAURIGA SCIENCES INC., a Florida corporation, with headquarters located at 4 Nancy Court, Suite 4, Wappingers Falls, New York 12590 (the ?Company?), and MBS GLOEQ CORP., a New York corporation, with its address at 12 Sagamore Way, South Jericho, New York 1175 |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, |
|
| November 15, 2021 |
Securities Purchase Agreement with GS Capital Partners, LLC dated August 25, 2021 Exhibit 4.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of August 25, 2021, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the ?Company?), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the ?Buyer?). W |
|
| November 15, 2021 |
Securities Purchase Agreement with Jefferson Street Capital LLC dates September 20, 2021 Exhibit 4.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 20, 2021, by and between TAURIGA SCIENCES INC., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, New York 10022 (the ?Company?), and JEFFERSON STREET CAPITAL LLC, a New Jersey limited liability company, with its address at 720 Monroe Stre |
|
| November 15, 2021 |
Inventory Financing Promissory Note with Jefferson Street Capital LLC dated September 20, 2021 Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registration [X] Filed by a Party other than the Registrant [??] Check the appropriate box: [X] Preliminary Proxy Statement [??] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30 |
|
| August 16, 2021 |
Securities Purchase Agreement with SE Holdings dated August 6, 2021 Exhibit 4.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of August 6, 2021 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 4 Nancy Court, Suite 4, Wappingers Falls, NY 12590 (the ?Company?), and SE HOLDINGS, LLC, a Nevada limited liability company, with its address at 6130 W. Flamingo Rd. #1878, Las Vegas, N |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, INC. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No.1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2020 to March 31, 2021 Commission |
|
| August 16, 2021 |
Exhibit 4.2 4 Nancy Court, Ste 4 / Wappingers Falls, NY 12540 Cent Per Share Private Placement SECURITIES PURCHASE AGREEMENT (FIXED PRICE EQUITY PRIVATE PLACEMENT Tauriga Sciences Inc. (OTCQB: TAUG) 4 Nancy Court, Suite 4 Wappingers Falls, NY 12540 Attn: Seth M. Shaw, Chief Executive Officer. DATE: THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of , 2021, by and among Tauriga Scie |
|
| August 16, 2021 |
Promissory Note with SE Holdings for $115,000 dated August 6, 2021 Exhibit 10.6 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| July 23, 2021 |
Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom Exhibit 99.5 Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom Press Release | 07/21/2021 NEW YORK, NY, July 21, 2021 (GLOBE NEWSWIRE) ? via NewMediaWire ? Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or the ?Company?), a New York based diversified Life Sciences Company, today announced that it has commenced sales of its Tauri-Gum? product line in the Uni |
|
| July 23, 2021 |
Exhibit 99.3 Tauriga Sciences, Inc. and Think BIG, LLC Confirm the Launch of Two Limited-Edition Frank White/Tauri-Gum Versions Press Release | 07/09/2021 NEW YORK, NY, July 09, 2021 (GLOBE NEWSWIRE) ? via NewMediaWire ? Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or the ?Company?), a New York-based diversified Life Sciences Company, today provided shareholders with the following update, on it |
|
| July 23, 2021 |
Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum Exhibit 99.2 Amazon Brand Registry Approves the Application for the Company?s Flagship Brand: Tauri-Gum Press Release | 07/06/2021 NEW YORK, NY, July 06, 2021 (GLOBE NEWSWIRE) ? via NewMediaWire ? Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or the ?Company?), a New York-based diversified Life Sciences Company, today announced that its Brand Registry Application for its flagship Tauri-Gum? bran |
|
| July 23, 2021 |
Exhibit 99.1 Tauriga Sciences, Inc. Teams Up with No Excuses Enterprises, LLC and its Founder, NFL Hall of Famer Ray Lewis, to Leverage Additional Market Opportunities Press Release | 06/30/2021 The Initial Focus of this Partnership will be Aimed at the World of Professional Sports NEW YORK, NY, June 30, 2021 (GLOBE NEWSWIRE) ? via NewMediaWire ? Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or |
|
| July 23, 2021 |
Other Events, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 23, 2021 |
Exhibit 99.4 Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip BalmPress Release | 07/12/2021 NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) ? via NewMediaWire ? Tauriga Sciences, Inc. (OTCQB: TAUG) (?Tauriga? or the ?Company?), a New York based diversified Life Sciences Company, today introduces its two newest, innovative, |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2020 to March 31, 2021 Commission File Number: 000-5 |
|
| June 29, 2021 |
Non-convertible note with GS Capital Partners LLC dated March 5, 2021* Exhibit 10.31 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $273, |
|
| June 29, 2021 |
Securities Purchase Agreement with GS Capital Partners LLC dated March 5, 2021* Exhibit 4.38 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of March 5, 2021 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 4 Nancy Court, Suite 4, Wappingers Falls, NY 12590 (the ?Company?), and GS CAPITAL PARTNERS, LLC, a New York limited liability company, with its address at 30 Washington Street, Suite 5L |
|
| June 29, 2021 |
Investment agreement with SciSparc Ltd. dated March 1, 2021 Exhibit 10.28 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 1, 2021, between SciSparc Ltd., a company organized under the laws of Israel (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms a |
|
| June 29, 2021 |
Form of Securities Purchase agreement between Aegea Biotechnologies, Inc.* Exhibit 4.35 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this ?Agreement?) is made and entered into as of April , 2020, by and among Aegea Biotechnologies, Inc., a Delaware corporation (the ?Company?), and Tauriga Sciences, Inc., a Delaware corporation (?Investor?). Whereas, the Company desires to sell to the Investor, and the Investor desires to purchase from the Company |
|
| June 29, 2021 |
Strategic marketing and consulting agreement with Mayer and Associated dated June 14, 2021 Exhibit 10.27 This Consulting Agreement (the ?Agreement?) is made and entered into to be effective as June 14, 2021 (the ?Effective Date?) between Mayer & Associates or its designees with offices located at NY NY (the ?Consultant?) and Tauriga Sciences (TAUG) or any surviving company (??the Company?). The Company and the Consultant are sometimes referred to individually, as a ?Party? and collectiv |
|
| June 29, 2021 |
Exhibit 10.24 RELEASE This Release is between Aegea Biotechnologies, Inc., a Delaware corporation (?Sanarus?) and Tauriga Sciences, Inc. and its founder Seth Shaw (collectively, ?Releasors?). Each of Aegea and Releasors shall collectively be deemed to be ?parties? under this Agreement, and are entering into this Agreement as of the date set forth above. RECITALS A. Aegea and Releasors have entered |
|
| June 29, 2021 |
Securities Purchase Agreement with GS Capital Partners LLC dated April 30, 2021* Exhibit 4.37 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of April 30, 2021, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the ?Company?), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the ?Buyer?). W |
|
| June 29, 2021 |
Exhibit 10.25 MEMBERHSIP UNIT PURCHASE AGREEMENT THIS MEMBERSHIP UNIT PURCHASE AGREEMENT (this ?Agreement?), dated as of February 5, 2021, by and among Paz Gum LLC, a Nevada limited liability company, located at 32 Pine Tree Drive, Poughkeepsie, NY 12603 (the ?Company?), and the Investor identified on the signature pages hereto (individually, an ?Investor? and collectively, the ?Investors?). BACKG |
|
| June 29, 2021 |
Board advisory agreement with Dr. Loucks dated May 15, 2021 Exhibit 10.26 Consulting Agreement Medical Advisory Agreement: Field of Orthopedic Surgery ADVISORY BOARD AGREEMENT Director of Medical Practice Strategy / Director Medical (?DM?) NON AFFILIATE / NON FIDUCIARY CONSULTING POSITION Tauriga Sciences Inc. 4 Nancy Court, Suite # 4 Wappingers Falls, NY 12590 TITLE FOR Dr. Craig Loucks: ADVISORY BOARD (Medical) AGREEMENT DURATION: 24 Months (May 15, 2021 |
|
| June 29, 2021 |
Non-convertible note with GS Capital Partners LLC dated April 30, 2021* Exhibit 10.30 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $313, |
|
| June 29, 2021 |
Warrant Subscription Agreement with VistaGen Therapeutics, Inc. dated December 6, 2019* Exhibit 10.23 SUBSCRIPTION AGREEMENT WARRANTS VistaGen Therapeutics, Inc., a Nevada corporation (the ?Company?) Purchase of Warrants of the Company Instructions: Complete and sign this Subscription Agreement. Please be sure to initial the appropriate ?Accredited Investor? category in Box C. A completed and originally executed copy of, and the other documents required to be delivered with, this Sub |
|
| June 29, 2021 |
Convertible note with Tangiers Global LLC dated April 5, 2021* Exhibit 10.29 -Note: April 5, 2021 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2021 |
Security Purchase Agreement with SE Holding LLC for $110,000 dated November 11, 2020 Exhibit 4.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of November 11, 2020 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the ?Company?), and SE HOLDINGS, LLC, a Nevada limited liability company, with its address at 6130 W. Flamingo Rd. #1878, Las Vegas, |
|
| February 22, 2021 |
Form of Tauriga Security Purchase Agreement offered to accredited investors for private placement EX-4.4 3 ex4-4.htm Exhibit 4.4 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 31, 2020, by and among Tauriga Sciences, Inc., a Florida corporation with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and the Investor identified on the signature pages hereto (individually, an “Investor” and collect |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENC |
|
| February 22, 2021 |
Promissory Note with SE Holding LLC for $110,000 dated November 11, 2020 bearing 12% interest Exhibit 10.7 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on For |
|
| January 27, 2021 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 Tauriga Sciences, Inc. Signs Major Distribution Agreement with Online Grocer and Wholesaler, Stock Up Express NEW YORK, NY, Jan. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gu |
|
| January 27, 2021 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| January 27, 2021 |
Exhibit 10.1 Distribution Agreement This Distribution Agreement (this “Agreement”), dated as of February 1, 2021, is entered into between Tauriga Sciences, Inc., a Florida corporation (“Seller”) and Bozzuto’s Inc., a Connecticut corporation, through its Stock Up Express division (“Distributor,” and together with Seller, the “Parties,” and each, a “Party”). WHEREAS, Seller is in the business of pro |
|
| January 8, 2021 |
As filed with the Securities and Exchange Commission on January 8, 2021 Registration No. |
|
| January 8, 2021 |
Exhibit 10.1 LEASE dated January 6 , 2021 between CONTRAIL LLC as Landlord and TAURIGA SCIENCES, INC. as Tenant Affecting premises commonly known as 4 Nancy Court, Suite 4, Wappingers Falls, New York located in the Town of East Fishkill, New York. INDEX 1. The Demised Premises 2. Lease Term 3. Rent 4. Use of Demised Premises 5. Alterations and Additions 6. Condition of Demised Premises 7. Maintena |
|
| January 8, 2021 |
Other Events, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2021 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 Tauriga Sciences, Inc.’s Board of Directors Unanimously Votes to Terminate Its Equity Line of Credit Due to Substantially Improved Fundamentals, Macro-Business Outlook, and Balance Sheet NEW YORK, NY, Jan. 07, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life science |
|
| December 29, 2020 |
Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (hereinafter “Agreement”) effective as of the date when signed by both parties (the “Effective Date”), will set forth the terms and conditions between Tauriga Inc. a New York USA company, having a place of business at 555 Madison Avenue, 5th floor, NY, New York 10022 (hereinafter “Client”) and Clinical Strategies and Tactics, In |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| December 29, 2020 |
Exhibit 4.1 Note: December 22, 2020 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| December 28, 2020 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TAURIGA SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 87669X205 (CUSIP Number) December 28, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| November 19, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| November 19, 2020 |
Exhibit 10.2 AMENDMENT TO REGISTRATION RIGHTS AGREEMENT WITH TANGIERS GLOBAL, LLC DATED JANUARY 21, 2020 This Amendment (“Amendment”) is entered into and effective as of November 18, 2020 (the “Effective Date”) by and between Tauriga Sciences, Inc. (the “Company”) and Tangiers Global, LLC (“Tangiers”) in order to amend the Registration Rights Agreement entered into on January 21, 2020 by and betwe |
|
| November 19, 2020 |
Exhibit 10.1 AMENDMENT TO INVESTMENT AGREEMENT WITH TANGIERS GLOBAL, LLC DATED JANUARY 21, 2020 This Amendment (“Amendment”) is entered into and effective as of November 18, 2020 (the “Effective Date”) by and between Tauriga Sciences, Inc. (the “Company”) and Tangiers Global, LLC (“Tangiers”) in order to amend the Investment Agreement entered into on January 21, 2020 by and between the Company and |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIEN |
|
| November 16, 2020 |
Exhibit 10.8 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| November 16, 2020 |
Form of Private Placement Stock sale agreements for shares issued and funds received Exhibit 4.1 555 Madison Ave, 5th Fl / New York, NY 10022 2.75 Cent Per Share Private Placement SECURITIES PURCHASE AGREEMENT Tauriga Sciences Inc. (OTCQB: TAUG) 555 Madison Avenue, 5th Floor New York, NY 10022 Attn: Seth M. Shaw, Chief Executive Officer. DATE: , 2020 THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of , 2020, by and among Tauriga Sciences, Inc., a Florida corporatio |
|
| November 16, 2020 |
Securities Purchase Agreement with Jefferson Street Capital, LLC date October 5, 2020 Exhibit 4.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 5, 2020, by and between TAURIGA SCIENCES INC., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, New York 10022 (the “Company”), and JEFFERSON STREET CAPITAL LLC, a New Jersey limited liability company, with its address at 720 Monroe Street, |
|
| October 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commissio |
|
| October 1, 2020 |
Exhibit 10.3 |
|
| October 1, 2020 |
Exhibit 10.1 LICENSE AGREEMENT This License Agreement (this “Agreement”), dated September 24, 2020 (the “Effective Date”), is made and entered into by and between Tauriga Sciences, Inc., a Delaware corporation, with an address of 555 Madison Avenue, 5th Floor, New York, NY 10022 (“Licensee”), and Think Big, LLC, a Delaware limited liability company, with an address of 1920 Hillhurst Avenue, #120, |
|
| October 1, 2020 |
Exhibit 10.2 PROFESSIONAL SERVICES AGREEMENT This Professional Services Agreement (this “Agreement”) is dated as of September 24 2020 (the “Effective Date”), and made and entered into by and among Tauriga Sciences Inc., a Delaware corporation (the “Company”), and Christopher J. Wallace (“Brand Ambassador”). Each of the Company and the Brand Ambassador may each be referred to herein as a “Party” an |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, |
|
| August 14, 2020 |
Amended Collaboration agreement with Aegea Biotechnologies Inc. dated August 10, 2020 Exhibit 10.5 AMENDMENT TO COLLABORATION AGREEMENT This Amendment to Collaboration Agreement (this “Amendment”) is effective as of August 10, 2020 (the “Effective Date”) and amends that certain Collaboration Agreement dated April 3, 2020 (the “Agreement”) between Aegea Biotechnologies, Inc. (“Aegea”) and the Tauriga Sciences, Inc. (“Tauriga”). WHEREAS, the Parties wish to amend the Agreement as pro |
|
| July 22, 2020 |
Exhibit 10.1 Agreement to Appoint Dr. Keith Aqua to the following Position: CHIEF MEDICAL OFFICER (“CMO”) Tauriga Sciences Inc. 555 Madison Avenue, 5th Floor New York, NY 10022 Keith Aqua MD: Chief Medical Officer AGREEMENT DURATION: 12 Months (July 15, 2020 thru July 15, 2021), the “Term”. This Comprehensive Consulting Agreement (this “Agreement”) is made effective as of July 15, 2020 by and betw |
|
| July 22, 2020 |
Tauriga Sciences, Inc. Appoints Dr. Keith Aqua to Position of Chief Medical Officer Exhibit 99.1 Tauriga Sciences, Inc. Appoints Dr. Keith Aqua to Position of Chief Medical Officer Press Release | 07/20/2020 Dr. Aqua has been a Principal Investigator on Over 300 Pharmaceutical Industry-Sponsored Clinical Trials Wellington, FL, July 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified li |
|
| July 22, 2020 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 14, 2020 |
Exhibit 99.1 Tauriga Sciences, Inc. and Mr. Checkout Distributors Sign Distribution Agreement to Launch Tauri-Gum Nationwide to as Many as 200,000 Retail Stores & Locations Press Release | 07/06/2020 This Launch of Tauri-Gum™ will be Supported by a National Network of More than 1,100 Independent Direct Store Delivery (“DSD”) Distributors NEW YORK, NY, July 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAW |
|
| July 14, 2020 |
Mr. Checkout distributor agreement dated June 29, 2020 filed on Current Report 8-k on July 14, 2020 EX-10.1 4 ex10-1.htm Exhibit 10.1 381 SOUTH CENTRAL AVE. OV I E D O, F L 3 2 7 6 5 GO-TO-MARKET DIRECT TO DISTRIBUTOR AGREEMENT All changes or additions to the agreement will be considered binding when agreed upon by Mr. Checkout and the Company through any form of written consent, including email communication. By signing below, the Company agrees to any services agreed upon by both parties in wr |
|
| July 14, 2020 |
Exhibit 10.2 PRODUCT PLACEMENT MEMBERSHIP AGREEMENT This Product Placement Membership Agreement (“Agreement”), dated as of July 10th, 2020 (the “Effective Date”), is entered into by and between TAURIGA SCIENCES, INC. a Florida corporation (“Client”), and KushCo Holdings, Inc., a Nevada corporation (“Placement Agent”), collectively referred to as the “Parties” and each a “Party” and is based upon t |
|
| July 14, 2020 |
Exhibit 4.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $33,000 |
|
| July 14, 2020 |
Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 4, 2020, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”). WHER |
|
| July 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission File |
|
| June 30, 2020 |
Exhibit 4.64 Note: June 24, 2020 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2019 to March 31, 2020 Commission File Number: 000-5 |
|
| June 30, 2020 |
Warrant Subscription Agreement with VistaGen Therapeutics, Inc. dated December 6, 2019* Exhibit 10.23 SUBSCRIPTION AGREEMENT WARRANTS VistaGen Therapeutics, Inc., a Nevada corporation (the “Company”) Purchase of Warrants of the Company Instructions: Complete and sign this Subscription Agreement. Please be sure to initial the appropriate “Accredited Investor” category in Box C. A completed and originally executed copy of, and the other documents required to be delivered with, this Sub |
|
| June 30, 2020 |
Exhibit 10.22 NON-EXCLUSIVE DISTRIBUTION AGREEMENT FOR REGION OF NEW JERSEY (NORTHEAST USA) DURATION: 12-Month (“1 Year”) Agreement This Amended and Restated Comprehensive Distribution Agreement (this “Agreement”) is made effective as of April 30, 2019 by and between Tauriga Sciences Inc (OTCQB: TAUG) (“TAUG” or “Tauriga”), a Florida corporation, with a principal address of 555 Madison Avenue, 5th |
|
| June 30, 2020 |
Form of Securities Purchase agreement between Aegea Biotechnologies, Inc.* Exhibit 4.63 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of April , 2020, by and among Aegea Biotechnologies, Inc., a Delaware corporation (the “Company”), and Tauriga Sciences, Inc., a Delaware corporation (“Investor”). Whereas, the Company desires to sell to the Investor, and the Investor desires to purchase from the Company |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 3, 2020 |
Exhibit 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $55,00 |
|
| June 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 3, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 17, 2020, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”). W |
|
| June 3, 2020 |
Exhibit 10.5 Note: May 8, 2020 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA |
|
| June 3, 2020 |
Exhibit 10.4 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $44,00 |
|
| June 3, 2020 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 30, 2020 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and ADAR ALEF, LLC, a New York limited liability company, with its address at 38 Olympia Ln, Monsey, NY 10952 (the “Bu |
|
| June 3, 2020 |
Exhibit 10.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 18, 2020, by and between TAURIGA SCIENCES, INC., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Aven |
|
| June 3, 2020 |
Exhibit 10.7 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| April 15, 2020 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 17, 2020 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and ADAR ALEF, LLC, a New York limited liability company, with its address at 38 Olympia Ln, Monsey, NY 10952 (the “Bu |
|
| April 15, 2020 |
Exhibit 10.1 Collaboration Agreement This Collaboration Agreement (“Agreement”) is entered into as of April 3, 2020 (the “Effective Date”) by and between Tauriga Sciences Inc. (“Tauriga”) and Aegea Biotechnologies Inc. (“Aegea”) for the purpose of together developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity (the “SARS-Col 2 Test |
|
| April 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 15, 2020 |
Exhibit 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $44,00 |
|
| April 15, 2020 |
Exhibit 10.4 Note: March 23, 2020 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| April 15, 2020 |
Exhibit 99.1 Tauriga Sciences Inc. and Aegea Biotechnologies Inc. Enter into Collaboration Agreement to Develop a Rapid, Multiplexed Novel Coronavirus (COVID-19) Test Designed to Exhibit Superior Performance Press Release | 04/07/2020 NEW YORK, NY and SAN DIEGO, CA, April 07, 2020 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. |
|
| March 12, 2020 |
TAUG / Tauriga Sciences, Inc. CORRESP - - March 12, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| March 5, 2020 |
TAUG / Tauriga Sciences, Inc. S-1 - Registration Statement - S-1 1 forms-1.htm As filed with the U.S. Securities and Exchange Commission on March 5, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tauriga Sciences, Inc. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation or organization |
|
| March 5, 2020 |
Exhibit 4.89 AMENDED AND RESTATED 10% PROMISSORY NOTE This AMENDED AND RESTATED 10% PROMISSORY NOTE is made and entered into as of February 28, 2020 by and between Tauriga Sciences, Inc., a Florida corporation (the “Company”), with its principal executive offices at , and Tangiers Global, LLC (the “Investor”), a Wyoming limited liability company, with its principal executive offices at Caribe Plaz |
|
| March 5, 2020 |
Exhibit 4.88 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| February 13, 2020 |
Exhibit 10.13 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 15, 2020 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and ADAR ALEF, LLC, a New York limited liability company, with its address at 38 Olympia Ln, Monsey, NY 10952 (the |
|
| February 13, 2020 |
TAUG / Tauriga Sciences, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENC |
|
| February 13, 2020 |
Exhibit 10.14 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $44,0 |
|
| February 13, 2020 |
Exhibit 10.16 JOINT VENTURE PARTNERSHIP AGREEMENT This JOINT VENTURE PARTNERSHIP AGREEMENT (“Agreement”) is made and executed on this 21 Day of January, 2020 by and between: OG LABRATORIES, LLC, a Florida Limited Liability Company (“Company”), and SETH SHAW, (Tauriga Sciences ). RECITALS: A. Contractor, by and through his entity TAURIGA SCIENCES INC., has an existing relationship with Company as a |
|
| February 13, 2020 |
Exhibit 10.15 Note: February 6, 2020 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STA |
|
| January 29, 2020 |
Exhibit 10.4 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $110,0 |
|
| January 29, 2020 |
Exhibit 99.1 Financing Agreement Supports the Company’s Ongoing Efforts to Develop Pharmaceutical Anti-Nausea Product NEW YORK, NY, Jan. 23, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of |
|
| January 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| January 29, 2020 |
Registration Rights Agreement, dated January 21, 2020 filed on Form 8-K on January 29, 2020 Exhibit 10.2 |
|
| January 29, 2020 |
Exhibit 10.1 |
|
| January 29, 2020 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 17, 2020, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”). |
|
| January 9, 2020 |
Tauriga Sciences, Inc. Finalizes the Formulation for its 15mg Vegan CBD Infused Gummies; Product Branded as: Tauri-Gummies Press Release | 11/25/2019 NEW YORK, NY, Nov. 25, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary produc |
|
| January 9, 2020 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 9, 2020 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $100,000. |
|
| January 9, 2020 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 9, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 18, 2019 by and between Tauriga Sciences, Inc. |
|
| January 9, 2020 |
555 Madison Ave, 5th Fl / New York, NY 10022 SECURITIES PURCHASE AGREEMENT Tauriga Sciences Inc. |
|
| January 9, 2020 |
Tauriga Sciences, Inc. Certified by Walmart Inc. to Become a Domestic Supplier Tauriga Sciences, Inc. Certified by Walmart Inc. to Become a Domestic Supplier GlobeNewswire ● December 23, 2019 NEW YORK, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of poten |
|
| January 9, 2020 |
Tauriga Sciences, Inc. Approved by Alibaba Group to Operate Global Seller Account Tauriga Sciences, Inc. Approved by Alibaba Group to Operate Global Seller Account Flagship Product Tauri-Gum™ Successfully Listed on Alibaba.com NEW YORK, NY, Jan. 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as |
|
| January 9, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 26, 2019, by and between TAURIGA SCIENCES INC. |
|
| January 9, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 3, 2020, by and between TAURIGA SCIENCES INC. |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2020 |
Tauriga Sciences Inc. Certified as Affiliate Vendor by The National Association of College Stores Tauriga Sciences Inc. Certified as Affiliate Vendor by The National Association of College Stores NEW YORK, NY, Jan 07, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition |
|
| January 9, 2020 |
Tauriga Sciences, Inc. Commences Development of Cannabigerol “CBG” Isolate Infused Version of Tauri-Gum GlobeNewswire ● December 30, 2019 Flavor: Starfruit/Peach Blister Pack Design for Starfruit/Peach Flavor - CBG Infused - Tauri-Gum™ NEW YORK, NY, Dec. 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating company th |
|
| December 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2019 |
BHP Capital NY, Inc Convertible Promissory note dated October 17, 2019 filed November 12, 2019 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| November 12, 2019 |
Tangiers Global, LLC 10% Convertible Promissory Note dated November 5, 2019 filed November 12, 2019 -Note: November 5, 2019 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. |
|
| November 12, 2019 |
TAUG / Tauriga Sciences, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIEN |
|
| November 12, 2019 |
BHP Capital NY, Inc. Securities Purchase Agreement dated October 7, 2019 filed November 12, 2019 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 3, 2019, by and between TAURIGA SCIENCES INC. |
|
| October 8, 2019 | ||
| October 8, 2019 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $100,000. |
|
| October 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commissio |
|
| October 8, 2019 |
Tauri-Gum™ Product Line – Now Encompasses Three Dynamic Flavors! Tauri-Gum™ Product Line – Now Encompasses Three Dynamic Flavors! Tauriga Sciences, Inc. |
|
| October 8, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 13, 2019 by and between Tauriga Sciences, Inc. |
|
| September 10, 2019 |
EX-99.1 2 ex99-1.htm Tauriga Sciences, Inc. Obtains Approval of its Stockholders to Increase its Authorized Common Stock at Special Shareholder Meeting New York, New York 09/10/2019. — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of |
|
| September 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commissio |
|
| August 15, 2019 |
TAUG / Tauriga Sciences, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registration [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive |
|
| August 13, 2019 |
TAUG / Tauriga Sciences, Inc. PRER14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registration [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| August 13, 2019 |
Agreement with Vice President of Distribution & Marketing date May 11, 2019 (filed herewith) TAURIGA SCIENCES INC. (OTCQB: TAUG) 555 Madison Avenue, 5” Floor New York, NY 10022 Attn: Seth M. Shaw, Chief Executive Officer SUB-AGREEMENT FOR NEELIMA LEKKALA {Pursuant to April 30, 2019 Distribution Agreement Entered into Between Tauriga Sciences Inc.& Sai Krishna LLC} Ms. Neelima Lekalla 27 Wingate Dfive Livingston, NJ 07039 SS # XXX-XX-4076 May 11, 2019 This (this “Agreement”), dated as of M |
|
| August 13, 2019 |
TAUG / Tauriga Sciences, Inc. CORRESP - - Tauriga Sciences, Inc. 555 Madison Avenue 5th Floor New York, NY T: +1 (917) 796-9926 August 13, 2019 Via Edgar Correspondence Ms. Christine Westbrook Office of Healthcare & Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Tauriga Sciences, Inc. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed August 7, 201 |
|
| August 13, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 22, 2019, by and between TAURIGA SCIENCES INC. |
|
| August 13, 2019 |
TAUG / Tauriga Sciences, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, |
|
| August 13, 2019 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| August 7, 2019 |
TAUG / Tauriga Sciences, Inc. PRER14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registration [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| August 7, 2019 |
TAUG / Tauriga Sciences, Inc. CORRESP - - August 7, 2019 Via Edgar Correspondence Ms. Christine Westbrook Office of Healthcare & Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Tauriga Sciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 29, 2019 File No. 000-53723 Dear Ms. Westbrook: We have received your correspondence dated August 5, 2019. We have |
|
| July 29, 2019 |
TAUG / Tauriga Sciences, Inc. PRE 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registration [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| July 18, 2019 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2019 (July 17, 2019) Tauriga Sciences, Inc. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction (Commission (I.R. |
|
| July 18, 2019 |
Changes in Registrant’s Certifying Accountant (filed on current report 8-K on July 18, 2019) Exhibit 16.1 July 18, 2019 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 We have read the statements that we understand Tauriga Sciences, Inc. (the “Registrant” or the “Company”) will include under Item 4.01 of the Form 8-K report it will file regarding the change in independent registered public accounting firms. We agree with such statements regarding our firm. Respectf |
|
| July 5, 2019 |
EX-10.1 2 ex10-1.htm DISTRIBUTION AGREEMENT THIS DISTRIBUTION AGREEMENT (the “Agreement”) is made effective as of the Effective Date between the Company and the Client, the definition of each of which are set forth on the annexed schedule. WHEREAS, Client wishes to grant to Company the right to distribute and sell certain nutritional products described on the Schedule annexed hereto (the “Products |
|
| July 5, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 27, 2019 |
GS Capital Partners, LLC Securities Purchase Agreement dated May 23, 2019 filed on June 27, 2019 EX-4.62 5 ex4-62.htm SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 23, 2019, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06180 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Broad Street, Suite 1201, New York, NY 10004 (the “Buyer”). WHEREAS |
|
| June 27, 2019 |
TAUG / Tauriga Sciences, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2018 to March 31, 2019 Commission File Number: 000-5 |
|
| June 27, 2019 |
GS Capital Partners, LLC Securities Purchase Agreement dated March 14, 2019 filed on June 27, 2019 EX-4.61 4 ex4-61.htm SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 14, 2019, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06180 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Broad Street, Suite 1201, New York, NY 10004 (the “Buyer”). WHERE |
|
| June 27, 2019 |
GS Capital Partners, LLC Convertible note dated March 14, 2019 for $300,000 filed on June 27, 2019 EX-4.60 3 ex4-60.htm THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) U |
|
| June 27, 2019 |
GS Capital, LLC Convertible note dated May 23, 2019 for $60,000 filed on June 27, 2019 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $60,000. |
|
| June 27, 2019 |
GS Capital Partners, LLC Securities Purchase Agreement dated June 21, 2019 filed on June 27, 2019 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 21, 2019, by and between Tauriga Sciences, Inc. |
|
| June 27, 2019 |
GS Capital Partners, LLC Convertible note dated June 21, 2019 for $60,000 filed on June 27, 2019 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $60,000. |
|
| May 30, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2019 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida 000-53723 30-0791746 (State or other jurisdiction of incorporation) (Commission File |
|
| May 30, 2019 | ||
| May 3, 2019 |
NEW YORK, NY, May 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: NEW YORK, NY, May 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. |
|
| May 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30-079 |
|
| May 3, 2019 |
Distribution Agreement between the Company and Sai Krishna LLC, dated April 30, 2019 NON-EXCLUSIVE DISTRIBUTION AGREEMENT FOR REGION OF NEW JERSEY (NORTHEAST USA) DURATION: 12-Month (“1 Year”) Agreement This Amended and Restated Comprehensive Distribution Agreement (this “Agreement”) is made effective as of April 30, 2019 by and between Tauriga Sciences Inc (OTCQB: TAUG) (“TAUG” or “Tauriga”), a Florida corporation, with a principal address of 555 Madison Avenue, 5th Floor New York, NY 10022 and Sai Krishna LLC (“SKL”), a New Jersey corporation (engaged in distribution, marketing, and fulfillment of products —mainly to the spirits industry and convenient stores), with its mailing address at 27 Wingate Drive // Livingston, NJ 07039. |
|
| April 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2019 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30-079 |
|
| April 15, 2019 |
NEW YORK, NY, April 09, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: NEW YORK, NY, April 09, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. |
|
| April 15, 2019 |
EX-4.1 2 ex4-1.htm COMPREHENSIVE DISTRIBUTION AGREEMENT —BETWEEN — DATED: March 20, 2019 Tauriga Sciences Inc. (OTCQB: TAUG) (“TAUG” or “Tauriga”) 555 Madison Avenue, 5th Floor New York, NY 10022 And E & M Ice Cream Co. (“E & M”) 701 Zerega Avenue Bronx, NY 10473 Re: Distribution of Tauriga’s CBD Infused Chewing Gum Product Line (Branded as Tauri-Gum™) focusing on the New York City Metropolitan Ar |
|
| April 15, 2019 |
New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: EX-99.1 7 ex99-1.htm New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has reached an agreemen |
|
| April 15, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 14, 2019, by and between Tauriga Sciences, Inc. |
|
| April 15, 2019 |
NEW YORK, NY, March 18, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: NEW YORK, NY, March 18, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Tauriga Sciences, Inc. |
|
| April 15, 2019 |
GS Capital Note, dated March 14, 2019 filed on current report 8-K on April 15, 2019 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $300,000. |
|
| April 15, 2019 |
SECURITIES PURCHASE AGREEMENT Tauriga Sciences Inc. (OTCQB: TAUG) 555 Madison Avenue, 5th Floor New York, NY 10022 Attn: Seth M. Shaw, Chief Executive Officer. DATE: March , 2019 THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March , 2019, by and among Tauriga Sciences, Inc., a Florida corporation (the “Company”), and the Subscriber identified on the signature pages hereto (the |
|
| April 15, 2019 |
NON-EXCLUSIVE DISTRIBUTION AGREEMENT FOR REGION OF SOUTH FLORIDA This Amended and Restated Comprehensive Distribution Agreement (this “Agreement”) is made effective as of April 8, 2019 by and between Tauriga Sciences Inc. |
|
| January 29, 2019 |
PER OS BIOSCIENCES CONTRACT MANUFACTURING AGREEMENT FOR CHEWING GUM Terms and Conditions 1. |
|
| January 29, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 20, 2018, by and between TAURIGA SCIENCES, INC. |
|
| January 29, 2019 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 15, 2019, by and between TAURIGA SCIENCES, INC. |
|
| January 29, 2019 |
EX-10.12 12 ex10-12.htm TAURIGA SCIENCES INC. (OTCQB: TAUG) 555 Madison Avenue, 5’h Floor New York, NY 10022 Attn: Seth M. Shaw, Chief Executive Officer AGREEMENT FOR CONSULTANT TO THE COMPANY With J. Safier Enterprises LLC January 11, 2019 This (this “Agreement”), dated as of January 11, 2019 (the “Effective Date”), by and between Tauriga Sciences Inc., located in New York, NY 10022 (the “Company |
|
| January 29, 2019 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| January 29, 2019 |
SECURITIES PURCHASE AGREEMENT Tauriga Sciences Inc. (OTCQB: TAUG) 555 Madison Avenue, 5th Floor New York, NY 10022 Attn: Seth M. Shaw, Chief Executive Officer. DATE: January 8, 2019 THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 8, 2019, by and among Tauriga Sciences, Inc., a Florida corporation (the “Company”), and the Subscriber identified on the signature pages heret |
|
| January 29, 2019 |
TAUG / Tauriga Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENC |
|
| January 29, 2019 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $55,000. |
|
| January 29, 2019 |
EX-10.6 5 ex10-6.htm January 15, 2019 ClearTrust, LLC 16540 Pointe Village Dr, Ste 205 Lutz, FL 33558 Ladies and Gentlemen: Tauriga Sciences, Inc., a Florida corporation (the “Company”), and Eagle Equities, LLC (the “Investor”) have entered into a Securities Purchase Agreement (“SPA”) dated January 15, 2019, providing for the issuance of an 8% Convertible Promissory Note with a principal amount of |
|
| January 29, 2019 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $62,000. |
|
| January 29, 2019 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $55,000. |
|
| January 18, 2019 |
New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: New York, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has reached an agreement to extinguish the $ |
|
| January 18, 2019 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2019 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30-0 |
|
| October 31, 2018 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $180,000. |
|
| October 31, 2018 |
TAUG / Tauriga Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIEN |
|
| October 31, 2018 |
SETTLEMENT AND RELEASE OF TAURIGA SCIENCES, INC Between Tauriga Sciences Inc. & Solomon Sharbat (and all related entities) OCTOBER 23, 2018 This Settlement and Release (the “Agreement”) is made this 23rd day of October, 2018 by and between Seth Shaw and Tauriga Sciences, Inc., a Florida corporation (“also herein referenced as: “TAURIGA” TAUG” or the”Company”), having its principal place of busines |
|
| October 31, 2018 |
EX-10.2 4 ex10-2.htm SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 25, 2018, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06180 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Broad Street, Suite 1201, New York, NY 10004 (the “Buyer”). WHE |
|
| July 31, 2018 |
TAUG / Tauriga Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENCES, |
|
| July 31, 2018 |
8% Convertible note issued to GS Capital Partners, LLC dated May 10, 2018 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $28,000. |
|
| July 31, 2018 |
EX-10.1 2 ex10-1.htm SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 10, 2018, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06180 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 110 Wall Street, Suite 5-070, New York, NY 10005 (the “Buyer”). WHEREA |
|
| July 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2018 TAURIGA SCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Florida 000-53723 30-0791746 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| July 9, 2018 |
Articles of Amendment to the Articles of Incorporation of Tauriga Sciences, Inc. |
|
| July 9, 2018 |
Tauriga Sciences Inc. Receives Confirmation from FINRA that its Reverse Split will take Effect at Open of Trading Monday July 9, 2018; the Company’s Ticker Symbol will be Amended to “TAUGD” for a Period of 20 Business Days NEW YORK, NY, July 6, 2018 /PRNewswire/ Tauriga Sciences, Inc. (OTC PINK: TAUG) (OTC PINK: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the deve |
|
| June 27, 2018 |
TAUG / Tauriga Sciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2017 to March 31, 2018 Commission File Number: 000-5 |
|
| June 27, 2018 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $27,500. |
|
| June 27, 2018 | ||
| June 27, 2018 |
Group 10 Convertible Note Payable November 2016 (filed herewith) NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| June 27, 2018 |
Group 10 Convertible Note Payable issued July 2015 (filed herewith) NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| June 27, 2018 |
EX-4.41 9 ex4-41.htm THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) U |
|
| June 27, 2018 |
ADAR Bays issued December 2016 (filed herewith) EX-4.14 4 ex4-14.htm THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) U |
|
| June 27, 2018 |
BRIDGE LOAN AND SECURITY AGREEMENT Dated as of September 23, 2015 between TAURIGA SCIENCES INC. |
|
| June 27, 2018 |
12% Convertible redeemable note ADAR Bays issued August 15, 2017 (filed herewith) THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $60,950. |
|
| June 27, 2018 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $27,500. |
|
| June 27, 2018 |
HerMan license agreement filed with 2018 10-K on June 27, 2018 |
|
| June 27, 2018 |
2 year extension HerMan license agreement filed with 2018 10-K on June 27, 2018 EX-10.10 11 ex10-10.htm Exhibit 10.10 DATE: November 22, 2017 From: Tauriga Sciences Inc. 39 Old Ridgebury Road, Ste. C4 Danbury, CT 06810 CEO – Seth M. Shaw Emails: [email protected] Cell # (917)-796-9926 To: Ice + Jam LLC 4906 Bridge Avenue Cleveland, Ohio 44102 Co – CEO(s) - Jamie Murphy & Ivy Evans Re: AMENDMENT to AGREEMENT; Mutually Agreed Upon 2-Year Extension to Existing Non-Exclusive Lice |
|
| April 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2018 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30-0791 |
|
| February 16, 2018 |
Tauriga Sciences Inc. Gains Exposure to Electric Vehicle Infrastructure Market Segment through Strategic $191,250 USD Transaction NEW YORK, NY-(Marketwired ? February 14, 2018) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company?), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential ac |
|
| February 16, 2018 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30- |
|
| February 12, 2018 |
TAUG / Tauriga Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIENC |
|
| January 4, 2018 |
EX-99.1 2 ex99-1.htm Tauriga Sciences, Inc. to Diversify $25,000 of its Balance Sheet Cash into Groestlcoin and Gain Exposure to the Crypto Currency Sector NEW YORK, NY—(Marketwired - Dec 27, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluatio |
|
| January 4, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2017 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30- |
|
| December 22, 2017 |
Tauriga Sciences, Inc. Extinguishes its Largest Remaining Balance Sheet Liability for One Time Cash Payment of $15,000 and One Time Issuance of 5,000,000 Restricted Shares; Liability Dated Back to the Years 2010/2011 and Totaled $177,883.71 NEW YORK, NY?(Marketwired - Dec 22, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company?), engaged in building business through the deve |
|
| December 22, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30- |
|
| December 15, 2017 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2017 Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 30- |
|
| December 1, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2017 (December 1, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of |
|
| December 1, 2017 |
Tauriga Sciences, Inc. Announces Board Approval for Up to $150,000 Share Buy-Back Program Effective Immediately NEW YORK, NY ? (Marketwired ? December 1, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company?) today announced that the Board of Directors of the Company (the ?Board?) approved a share buyback program, authorizing the Company to buy back up to $150,000 of its comm |
|
| December 1, 2017 |
Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan NEW YORK, NY ? (Marketwired - November 29, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company?) today announced that it has decided to move its corporate headquarters from Danbury, Connecticut to Midtown Manhattan in New York City. The effective date of this relocation will be |
|
| December 1, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2017 (December 1, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of |
|
| November 28, 2017 |
Tauriga Sciences, Inc. and Group 10 Holdings LLC Reach Agreement to Fully Extinguish the $348,000 Assessed Liquidated Damage Total NEW YORK, NY ? (Marketwired - November 28, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company?) today announced that it has reached an agreement (the ?Agreement?) with Group 10 Holdings LLC (?Group 10?) to fully extinguish the $348,000 assessed |
|
| November 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2017 (November 28, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction o |
|
| November 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2017 (March 31, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other |
|
| November 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 (November 9, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of |
|
| November 13, 2017 |
EX-99.1 2 ex99-1.htm Tauriga Sciences Inc. Enters into Confidential Settlement Agreement and General Releases in Connection with the Action Against its Former Auditors On November 09, 2017 (the “Effective Date”), Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”) entered into a Confidential Settlement Agreement and General Releases (the “Settlement Agreement”) in connection with |
|
| November 13, 2017 |
TAUG / Tauriga Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ] TRANSTITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53723 TAURIGA SCIE |
|
| October 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 (October 17, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of |
|
| October 23, 2017 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $105,000. |
|
| October 23, 2017 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| October 23, 2017 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $105,000. |
|
| October 23, 2017 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of October 17, 2017, by and between Tauriga Sciences, Inc. |
|
| October 13, 2017 |
TAUG / Tauriga Sciences, Inc. / Shaw Seth M Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* TAURIGA SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 87669X106 (CUSIP Number) Seth M. Shaw c/o Tauriga Sciences, Inc. 39 Old Ridgebury Road Danbury, Connecticut 06180 (917) 796-9926 (Name, Address and Telephone Number of Pe |
|
| October 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2017 (October 6, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of in |
|
| October 6, 2017 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of October 6, 2017, by and among Tauriga Sciences, Inc. |
|
| October 6, 2017 |
Tauriga Sciences, Inc. Chief Executive Officer Seth M. Shaw Invests Additional $137,500 USD into the Company Investment Structured as an Equity Private Placement Investment Priced at $0.00125 per share NEW YORK, NY?(Marketwired ? October 06, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (?Tauriga? or the ?Company? or ?Tauriga?), a company engaged in building businesses in the life sciences space |
|
| September 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2017 (September 11, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction |
|
| September 15, 2017 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 11, 2017, by and between Tauriga Sciences, Inc. |
|
| September 15, 2017 |
ADAR Bays Back End Note filed on current report 8-K September 15, 2017 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $30,000. |
|
| September 15, 2017 |
Tauriga Sciences, Inc. Secures $210,000 in Long Term Financing from Existing Institutional Investor EX-99.1 6 ex99-1.htm Tauriga Sciences, Inc. Secures $210,000 in Long Term Financing from Existing Institutional Investor NEW YORK, NY—(Marketwired - September 14, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced that it has secured $210,000 in long term financing from an existing insti |
|
| September 15, 2017 |
ADAR Bays Convertible Redeemable Note filed on current report 8-K dated September 15, 2017 EX-4.1 2 ex4-1.htm THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US |
|
| September 15, 2017 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| September 7, 2017 |
EX-10.2 7 ex10-2.htm SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 31, 2017, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 39 Old Ridgebury Road, Danbury, CT 06180 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 110 Wall Street, Suite 5-070, New York, NY 10005 (the “Buyer”). WHE |
|
| September 7, 2017 |
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| September 7, 2017 |
EX-4.2 3 ex4-2.htm THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US |
|
| September 7, 2017 |
EX-4.1 2 ex4-1.htm Amendment to Convertible Promissory Note Dated June 27, 2017 This Amendment to the Convertible Promissory Note issued by Tauriga Sciences, Inc (the “Company”) to GS Capital Partners, LLC (“GS”) on June 27, 2017 in the amount of $80,000 (“Note”) is entered into on this 31st day of August 2017. WHEREAS, the parties desire to amend Section 4(a) of the Note to read as follows: NOW T |
|
| September 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2017 (August 30, 2017) Commission File #: 000-53723 TAURIGA SCIENCES, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of |
